MRD对Ph+急性淋巴细胞白血病患者非血缘造血干细胞移植临床结局的影响:一项回顾性全国性研究
该回顾性全国性研究比较了715例连续成人Ph+急性淋巴细胞白血病完全缓解期患者接受单份非血缘脐血移植、HLA相合非血缘骨髓移植或HLA不合非血缘骨髓移植的结局。在MRD+队列中,三组调整后3年无白血病生存率分别为59.8%、38.3%和55.5%;MRD+的HLA相合骨髓移植组复发风险显著高于HLA不合骨髓移植组和脐血移植组。
要点
- MRD+队列中,脐血移植、HLA相合骨髓移植、HLA不合骨髓移植的3年无白血病生存率分别为59.8%、38.3%、55.5%。
- HLA相合骨髓移植组中MRD对死亡、复发或死亡、复发均有显著影响,而脐血移植和HLA不合骨髓移植组无此显著影响。
- 作者认为MRD阳性Ph+急性淋巴细胞白血病患者接受脐血移植或HLA不合骨髓移植可能较HLA相合骨髓移植降低白血病复发。
核心结论
- 数据表明MRD阳性的Ph+急性淋巴细胞白血病患者接受脐血移植或HLA不合非血缘骨髓移植而非HLA相合非血缘骨髓移植可能获益以降低白血病复发。
研究设计与样本
- 回顾性研究,纳入715例连续成人Ph+急性淋巴细胞白血病完全缓解期患者,接受单份非血缘脐血移植(n=232,4/6、5/6和6/6 HLA相合)、HLA相合非血缘骨髓移植(n=292,8/8 HLA相合)或HLA不合非血缘骨髓移植(n=191,7/8 HLA相合)。
主要发现
- MRD+队列中,脐血移植、HLA相合骨髓移植、HLA不合骨髓移植的调整后3年无白血病生存率分别为59.8%、38.3%、55.5%。
- MRD-队列中,脐血移植、HLA相合骨髓移植、HLA不合骨髓移植的调整后3年无白血病生存率分别为65.3%、70.4%、69.7%。
- MRD+的HLA相合骨髓移植组复发风险显著高于MRD+的HLA不合骨髓移植组(HLA不合骨髓移植组HR 0.33,95%CI 0.15-0.74)和MRD+的脐血移植组(脐血移植组HR 0.38,95%CI 0.18-0.83)。
- HLA相合骨髓移植中MRD对死亡有显著影响(HR 1.87,95%CI 1.19-2.94),对复发或死亡有显著影响(HR 2.24,95%CI 1.50-3.34),对复发有显著影响(HR 3.12,95%CI 1.75-5.57),而脐血移植和HLA不合骨髓移植无此显著影响。
临床怎么用
- 作者认为MRD阳性的Ph+急性淋巴细胞白血病患者接受脐血移植或HLA不合非血缘骨髓移植而非HLA相合非血缘骨髓移植可能获益以降低白血病复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Measurable residual disease (MRD) status before transplantation has been shown to be a strong prognostic factor in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). However, the outcomes of unrelated hematopoietic stem cell transplantation based on the MRD status have not been fully investigated. In this retrospective study, we compared the outcomes of 715 consecutive adults with Ph+ ALL in complete remission who underwent unrelated cord blood transplantation (UCBT) (single-unit UCBT, n = 232 [4/6, 5/6, and 6/6 HLA match]), HLA-matched unrelated bone marrow transplantation (UBMT; n = 292 [8/8 HLA match]), or HLA-mismatched UBMT (n = 191 [7/8 HLA match]). In the MRD+ cohort, adjusted 3-year leukemia-free survival rates were 59.8%, 38.3%, and 55.5% after UCBT, HLA-matched UBMT, and HLA-mismatched UBMT, respectively. In the MRD- cohort, the corresponding rates were 65.3%, 70.4%, and 69.7%, respectively. The MRD+ HLA-matched UBMT group had a significantly higher risk of relapse than the MRD+ HLA-mismatched UBMT group (hazard ratio [HR] in the MRD+ HLA-mismatched UBMT group, 0.33; 95% confidence interval [CI] 0.15-0.74) and the MRD+ UCBT group (HR in the MRD+ UCBT group, 0.38; 95% CI 0.18-0.83). Furthermore, HLA-matched UBMT had a significant effect of MRD on death (HR 1.87; 95% CI 1.19-2.94), relapse or death (HR 2.24; 95% CI 1.50-3.34), and relapse (HR 3.12; 95% CI 1.75-5.57), while UCBT and HLA-mismatched UBMT did not. In conclusion, our data indicate Ph+ ALL patients with positive MRD may benefit from undergoing UCBT or HLA-mismatched UBMT instead of HLA-matched UBMT to reduce leukemic relapse.
引用
- Hirabayashi S, Kondo T, Nishiwaki S, et al. Impact of MRD on clinical outcomes of unrelated hematopoietic stem cell transplantation in patients with Ph+ ALL: A retrospective nationwide study. Am J Hematol. 2023. PMID: 37493218. doi:10.1002/ajh.27041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。